Illustrative image – not actual.Avesthagen, on 13 May 2011, signed an MoU with Bangalore based Kemwell Biopharma.
As per the MoU signed between the two firms, Kemwell will perform technology transfer, process improvement, scale-up and manufacturing of pre clinical, clinical and commercial material of Avesthagen biosimilars. However, no financial details of the MOU were disclosed. Kemwell's 15,000 sq mtrs facility in Bengaluru will be used for producing biosimilars for Avesthagen.
Presently, Avesthagen has eight biosimilars under various phases of development in the areas of auto-immune diseases, cancers, anaemia and cardiovascular disorders.
